AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of $205.86 billion. The enterprise value is $230.43 billion.
Important Dates
The next confirmed earnings date is Thursday, February 6, 2025, before market open.
| Earnings Date | Feb 6, 2025 |
| Ex-Dividend Date | Aug 9, 2024 |
Share Statistics
AstraZeneca has 1.55 billion shares outstanding. The number of shares has increased by 0.22% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.55B |
| Shares Change (YoY) | +0.22% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.55B |
Valuation Ratios
The trailing PE ratio is 31.70 and the forward PE ratio is 14.70.
| PE Ratio | 31.70 |
| Forward PE | 14.70 |
| PS Ratio | n/a |
| Forward PS | 3.54 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 21.46 |
| P/OCF Ratio | 18.16 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 12.53, with an EV/FCF ratio of 24.02.
| EV / Earnings | 35.48 |
| EV / Sales | 4.50 |
| EV / EBITDA | 12.53 |
| EV / EBIT | 16.85 |
| EV / FCF | 24.02 |
Financial Position
The company has a current ratio of 0.93, with a Debt / Equity ratio of 0.77.
| Current Ratio | 0.93 |
| Quick Ratio | 0.71 |
| Debt / Equity | 0.77 |
| Debt / EBITDA | 1.69 |
| Debt / FCF | 3.30 |
| Interest Coverage | 10.12 |
Financial Efficiency
Return on equity (ROE) is 16.66% and return on invested capital (ROIC) is 12.28%.
| Return on Equity (ROE) | 16.66% |
| Return on Assets (ROA) | 8.50% |
| Return on Capital (ROIC) | 12.28% |
| Revenue Per Employee | $569,588 |
| Profits Per Employee | $72,247 |
| Employee Count | 89,900 |
| Asset Turnover | 0.51 |
| Inventory Turnover | 1.63 |
Taxes
In the past 12 months, AstraZeneca has paid $1.42 billion in taxes.
| Income Tax | 1.42B |
| Effective Tax Rate | 17.95% |
Stock Price Statistics
The stock price has decreased by -1.00% in the last 52 weeks. The beta is 0.18, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | -1.00% |
| 50-Day Moving Average | 65.98 |
| 200-Day Moving Average | 74.90 |
| Relative Strength Index (RSI) | 50.74 |
| Average Volume (20 Days) | 4,957,070 |
Short Selling Information
| Short Interest | 12.69M |
| Short Previous Month | 10.06M |
| Short % of Shares Out | 0.41% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.41 |
Income Statement
In the last 12 months, AstraZeneca had revenue of $51.21 billion and earned $6.50 billion in profits. Earnings per share was $4.15.
| Revenue | 51.21B |
| Gross Profit | 42.30B |
| Operating Income | 13.67B |
| Pretax Income | 7.74B |
| Net Income | 6.50B |
| EBITDA | 18.39B |
| EBIT | 13.67B |
| Earnings Per Share (EPS) | $4.15 |
Full Income StatementBalance Sheet
The company has $4.93 billion in cash and $31.61 billion in debt, giving a net cash position of -$26.68 billion or -$17.21 per share.
| Cash & Cash Equivalents | 4.93B |
| Total Debt | 31.61B |
| Net Cash | -26.68B |
| Net Cash Per Share | -$17.21 |
| Equity (Book Value) | 40.81B |
| Book Value Per Share | 26.27 |
| Working Capital | -1.77B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $11.33 billion and capital expenditures -$1.74 billion, giving a free cash flow of $9.59 billion.
| Operating Cash Flow | 11.33B |
| Capital Expenditures | -1.74B |
| Free Cash Flow | 9.59B |
| FCF Per Share | $6.19 |
Full Cash Flow StatementMargins
Gross margin is 82.61%, with operating and profit margins of 26.70% and 12.68%.
| Gross Margin | 82.61% |
| Operating Margin | 26.70% |
| Pretax Margin | 15.47% |
| Profit Margin | 12.68% |
| EBITDA Margin | 35.92% |
| EBIT Margin | 26.70% |
| FCF Margin | 18.73% |
Dividends & Yields
This stock pays an annual dividend of $1.48, which amounts to a dividend yield of 2.23%.
| Dividend Per Share | $1.48 |
| Dividend Yield | 2.23% |
| Dividend Growth (YoY) | 2.41% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 35.78% |
| Buyback Yield | -0.22% |
| Shareholder Yield | 2.01% |
| Earnings Yield | 3.16% |
| FCF Yield | 4.66% |
Dividend DetailsAnalyst Forecast
The average price target for AstraZeneca is $88.80, which is 33.33% higher than the current price. The consensus rating is "Buy".
| Price Target | $88.80 |
| Price Target Difference | 33.33% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 8.59% |
| EPS Growth Forecast (5Y) | 10.87% |
Stock ForecastsStock Splits
The last stock split was on July 27, 2015. It was a forward split with a ratio of 2:1.
| Last Split Date | Jul 27, 2015 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
AstraZeneca has an Altman Z-Score of 3.02 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.02 |
| Piotroski F-Score | 6 |